Johnson & Johnson logo

Johnson & Johnson (JNJ) Q1 2025 Earnings

JNJ·Reported April 15, 2025·Before market open

Johnson & Johnson reported Q1 2025 revenue of $21.9B, beat analyst consensus of $21.6B by $334.4M. Diluted EPS came in at $2.77, beat the $2.58 consensus by $0.19. Johnson & Johnson reports across 2 business segments, led by Innovative Medicine and MedTech.

Revenue
$21.9Bbeat by $334.4M
Consensus: $21.6B
Diluted EPS
$2.77beat by $0.19
Consensus: $2.58
SEC

SEC Filings

Earnings release8-K · 0000200406-25-000110
Quarterly report10-Q · 0000200406-25-000119

Financial Snapshot

Trailing eight quarters through Q1 2025

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q1 2025 Earnings FAQ

Common questions about Johnson & Johnson's Q1 2025 earnings report.

Johnson & Johnson (JNJ) reported Q1 2025 earnings on April 15, 2025 before market open.

Johnson & Johnson reported revenue of $21.9B and diluted EPS of $2.77 for Q1 2025.

Revenue beat the consensus estimate of $21.6B by $334.4M. EPS beat the consensus estimate of $2.58 by $0.19.

You can read the 8-K earnings release (0000200406-25-000110) and the 10-Q periodic report (0000200406-25-000119) directly on SEC EDGAR. The filing index links above go to sec.gov.